Literature DB >> 12176106

A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.

Sathapana Kongsamut1, Jiesheng Kang, Xiao-Liang Chen, Joachim Roehr, David Rampe.   

Abstract

Many antipsychotic drugs produce QT interval prolongation on the electrocardiogram (ECG). Blockade of the human cardiac K(+) channel known as human ether-a-go-go-related gene (HERG) often underlies such clinical findings. In fact, HERG channel inhibition is now commonly used as a screen to predict the ability of a drug to prolong QT interval. However, the exact relationship between HERG channel blockade, target receptor binding affinity and clinical QT prolongation is not known. Using patch-clamp electrophysiology, we examined a series of seven antipsychotic drugs for their ability to block HERG, and determined their IC(50) values. We then compared these results to their binding affinities (K(i) values) for the dopamine D(2) receptor, the 5-HT(2A) receptor and, where available, to clinical QT prolongation data. We found that sertindole, pimozide and thioridazine displayed little (<10-fold) or no selectivity for dopamine D(2) or 5-HT(2A) receptors relative to their HERG channel affinities. This lack of selectivity likely underlies the significant QT interval prolongation observed with administration of these drugs. Of the other drugs tested (ziprasidone, quetiapine, risperidone and olanzapine), olanzapine displayed the greatest selectivity for dopamine D(2) and 5-HT(2A) receptor binding (100-1000-fold) compared to its HERG channel IC(50). We also compared these HERG channel IC(50) values to QT interval prolongation and plasma drug levels obtained in a recent clinical study. We found that the ratio of total plasma drug concentration to HERG IC(50) value was indicative of the degree of QT prolongation observed. Target receptor affinity and expected clinical plasma levels are important parameters to consider for the interpretation of HERG channel data.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176106     DOI: 10.1016/s0014-2999(02)02074-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  45 in total

1.  How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.

Authors:  Dean Elbe; Robert Savage
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-02

2.  Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States.

Authors:  Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Warren B Bilker; Stephen E Kimmel; Brian L Strom; Sean Hennessy
Journal:  J Clin Exp Cardiolog       Date:  2013

Review 3.  Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Authors:  Karine Titier; Pierre-Olivier Girodet; Hélène Verdoux; Mathieu Molimard; Bernard Bégaud; Wilhelm Haverkamp; Malcolm Lader; Nicholas Moore
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Authors:  Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan
Journal:  Heart Rhythm       Date:  2006-04-22       Impact factor: 6.343

Review 5.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

6.  Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?

Authors:  Sayako Kamei; Noriko Sato; Yuta Harayama; Miyako Nunotani; Kanae Takatsu; Tetsuya Shiozaki; Tokutaro Hayashi; Hideki Asamura
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

Review 7.  Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Hiroyuki Uchida
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

8.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

Review 9.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

10.  A primate-specific, brain isoform of KCNH2 affects cortical physiology, cognition, neuronal repolarization and risk of schizophrenia.

Authors:  Stephen J Huffaker; Jingshan Chen; Kristin K Nicodemus; Fabio Sambataro; Feng Yang; Venkata Mattay; Barbara K Lipska; Thomas M Hyde; Jian Song; Dan Rujescu; Ina Giegling; Karine Mayilyan; Morgan J Proust; Armen Soghoyan; Grazia Caforio; Joseph H Callicott; Alessandro Bertolino; Andreas Meyer-Lindenberg; Jay Chang; Yuanyuan Ji; Michael F Egan; Terry E Goldberg; Joel E Kleinman; Bai Lu; Daniel R Weinberger
Journal:  Nat Med       Date:  2009-05-03       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.